RGDX: Summary for Response Genetics, Inc. - Yahoo! Canada Finance

	Sign In [New User? Sign Up]	Finance Home \|Help

Wednesday, November 25, 2009, 11:11am EST - Canadian Markets close in 4 hours and 49 minutes.

To create a watchlist or portfolio of shares, Sign-in or Register

Response Genetics, Inc (RGDX)

On Nov 23: 1.35 USD 0.00 (0.00%)

MORE ON RGDX

Quotes

Summary

Charts

News & Info

Company

Analyst Coverage

Ownership

Financials

Response Genetics, Inc. (NCM:RGDX) Delayed quote data

Last Trade:	1.35 USD
Trade Time:	Nov 23
Change:	0.00 (0.00%)
Prev Close:	1.35
Open:	N/A
Bid:	1.37 x 100
Ask:	1.50 x 200
1y Target Est:	7.50

Day's Range:	N/A - N/A
52wk Range:	0.29 - 2.74
Volume:	0
Avg Vol (3m):	21,493.9
Market Cap:	20.65M
P/E (ttm):	N/A
EPS (ttm):	-0.48
Div & Yield:	N/A (N/A%)

1d 5d 3m 6m 1y 2y 5y

Add RGDX to Portfolio

Download Data

HEADLINES

•	RESPONSE GENETICS INC Financials
	EDGAR Online Financials (Fri, Nov 20)

•	RESPONSE GENETICS INC Files SEC form 10-Q, Quarterly Report
	EDGAR Online (Mon, Nov 16)

•	Response Genetics, Inc. Reports Third Quarter 2009 Financial Results Driven by 100 Percent Increase in ResponseDX Revenues
	Business Wire (Mon, Nov 16)

•	Q3 2009 RESPONSE GENETICS INC Earnings Release - After Market Close
	CCBN (Mon, Nov 16)

•	Response Genetics, Inc. to Release Third Quarter 2009 Financial Results
	Business Wire (Fri, Nov 13)

•	Response Genetics Inc. Announces Nationwide Launch of New Gastric Cancer Diagnostic Test to Help Physicians Tailor Therapy for Patients
	Business Wire (Tue, Sep 29)

•	Arrowhead Research Corp. CEO and President Interview: Christopher Anzalone
	Wall Street Transcript (Tue, Sep 15)

•	RESPONSE GENETICS INC Files SEC form 8-K, Entry into a Material Definitive Agreement
	EDGAR Online (Thu, Sep 10)

•	Response Genetics, Inc. to Present at the Rodman & Renshaw 11th Annual Healthcare Conference
	Business Wire (Tue, Sep 8)

•	RESPONSE GENETICS INC Files SEC form 10-Q, Quarterly Report
	EDGAR Online (Fri, Aug 21)

More Headlines for RGDX...

ANALYST

EPS Est (next year) (Dec-07) :	N/A
EPS Est (in 2 years) (Dec-08) :	N/A
Avg Rec (current)*:	1.0
PEG Ratio:	N/A

* (Strong Buy) 1.0 - 5.0 (Strong Sell)

Analyst Opinion - Estimates

BUSINESS SUMMARY

Response Genetics, Inc. engages in the research and development of pharmacogenomic diagnostic tests for the treatment of cancer. It offers customizable menu of fee-based pharmacogenomics services, which support clinical trials that identify patien...

Full Company Profile

Add to Portfolio

Email to a Friend

•